Skip to main content
. Author manuscript; available in PMC: 2011 Dec 10.
Published in final edited form as: Arch Ophthalmol. 2008 Aug;126(8):1082–1088. doi: 10.1001/archopht.126.8.1082

Figure 2. The normal retinal vasculature is not effected by the VE-cadherin antagonist.

Figure 2

Representative images of vessels from d17 retinal whole mounts stained with FITC-GSA lectin. The vascular morphology and density of vessels within the retinal tissue is similar from animals treated with the VE-cadherin antagonist (A), the control peptide (B) or vehicle only (C).